Sorted By:

Relevance


Nikhil V. Dhurandhar, PhD

PhRMA  |  Biography

Dhurandhar has received research funding from the NIH, American Diabetes Association, Federal Emergency Management Agency, and other non-profit or commercial funding sources, has published over 100 scientific articles, and book chapters, and served as a mentor or advisor for several students and postdoctoral fellows.
https://www.phrma.org/biography/nikhil-v-dhurandhar-phd

Glenn J. Gormley, MD, PhD

PhRMA  |  Biography

He has remained committed to the fields of clinical pharmacology and endocrinology and published many papers of original research.
https://www.phrma.org/biography/glenn-j-gormley-md-phd

Medicare Plan Finder Is a Tool for Beneficiaries to Help Make Part D Plan Selections Each Year

Chartpack  |  From Our Network

Beneficiary choice of plans is a key feature of Part D’s competitive structure.
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/medicare-plan-finder-is-a-tool-for-beneficiaries-to-help-make-part-d-plan-selections-each-year

Medicare Part D: Then & Now

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/medicare-part-d-then-and-now

Medicare Monday: Catch up on MedPAC and its Part B recommendations

PhRMA  |  Blog Post

Put Part B spending on medicines into perspective and learn the facts.
http://catalyst.phrma.org/medicare-monday-catch-up-on-medpac-and-its-part-b-recommendations

Consumers Will Pay More Out Of Pocket Next Year For Specialty Drugs

Access Better Coverage  |  From Our Network

Increasingly, health plans –including those offered to people with job-based coverage – require hefty payments, sometimes 20 to 40 percent or more of the total cost of medications that insurers classify as specialty drugs.
http://www.accessbettercoverage.org/social-news/consumers-will-pay-more-out-of-pocket-next-year-for-specialty-drugs

Winning the War Against Counterfeiters

PhRMA  |  Blog Post

Like in our Conversations series, views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
http://catalyst.phrma.org/winning-the-war-against-counterfeiters

Past free trade agreements provide valuable lessons for future success

PhRMA  |  Blog Post

President Obama’s 2016 trade agenda will be the centerpiece of a hearing later this month, as well as a prime opportunity to bring up the lack of past trade agreement implementation.
http://catalyst.phrma.org/past-free-trade-agreements-provide-valuable-lessons-for-future-success

Patient Assistance

PhRMA  |  From PhRMA

Learn more about PPA by visiting www.pparx.org.
https://www.phrma.org/advocacy/access/patient-assistance

New Report: Past Drug Failures Help Create the War on Cancer’s Next Successes

PhRMA  |  Press Release

Research has shown that cancer is actually a set of more than 200 extremely complex diseases and discovering medicines that effectively treat each one is a difficult task.
https://www.phrma.org/press-release/new-report-past-drug-failures-help-create-the-war-on-cancer-s-next-successes

Yep, Obamacare Costs a Fortune

Access Better Coverage  |  From Our Network

 For a bronze plan, the insurer is meant to cover 60 percent of the cost of essential health care, on average, leaving beneficiaries to cover the rest.
http://www.accessbettercoverage.org/social-news/yep-obamacare-costs-a-fortune

PhRMA Statement on AARP Report

PhRMA  |  Press Release

“AARP’s report is misleading because nearly half of the drugs on its top 25 brand-name drug list were filled as generics in the first part of 2010, but AARP counts these drugs as if they were brand-name drugs.
https://www.phrma.org/press-release/phrma-statement-on-aarp-report

Never Too Late to Plan for Retirement

PhRMA  |  Blog Post

All of which is to say, it is never too late to start planning your financial future or to think about what we can all do to try and minimize the adverse effects that bad health - like a chronic disease - may have on our life and finances.
http://catalyst.phrma.org/never-too-late-to-plan-for-retirement

Average Beneficiary Premiums Are Far Below Original Estimates

Chartpack  |  From Our Network

Modest increases in premiums are going to make medications more affordable to Medicare beneficiaries, according to the Centers for Medicare & Medicaid Services.
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/average-beneficiary-premiums-are-far-below-original-estimates

Who Has a Seat at ICER's Table?

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/who-has-a-seat-at-icer-s-table

Lung-MAP Demonstrates Real Change in Cancer Research and Care Possible through Collaboration

PhRMA  |  Blog Post

The study has only just begun, but Lung-MAP has already successfully demonstrated that when leaders from all sectors collaborate to solve problems in cancer research and care, real change can happen.
http://catalyst.phrma.org/lung-map-demonstrates-real-change-in-cancer-research-and-care-possible-through-collaboration

Partnership for Prescription Assistance Celebrates Five Year Anniversary and Launch of ‘PPA 2.0’

PhRMA  |  Press Release

“As a patient who must cope every day with the effects of diabetes, I understand only too well the importance of having access to the medicine you need.”
https://www.phrma.org/press-release/partnership-for-prescription-assistance-celebrates-five-year-anniversary-and-launch-of-ppa-2-0

PhRMA Prescription Drug Abuse Position Paper

PhRMA  |  Policy Paper

However, prescription medicines can cause negative health consequences if they are used inappropriately and not as intended.  
https://www.phrma.org/policy-paper/phrma-prescription-drug-abuse-position-paper

PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis

PhRMA  |  Blog Post

Using PDMPs has proven to be an effective way to identify potential doctor shoppers and to foster appropriate prescribing but only when they are used and provide relevant data.
http://catalyst.phrma.org/phrma-supports-presidents-commissions-holistic-approach-on-opioid-crisis

Policy Solutions

PhRMA  |  Policy Paper

Modernizing Drug Discovery, Development and Approval We need to modernize the FDA to keep pace with scientific discovery and to enable a more competitive, innovative and sustainable ecosystem.
https://www.phrma.org/policy-paper/policy-solutions

Exchange Plan Transparency

Access Better Coverage  |  From Our Network

In our whiteboard video, we explain more about exchange plan transparency and what you can do until more information like this is available.
http://www.accessbettercoverage.org/video/exchange-plan-transparency

340B: Past and Present

Chartpack  |  From Our Network

When it was created in 1992, 340B was envisioned as a small program however insufficient guidance, historically weak oversight, and other factors have led to dramatic program growth, driven by the participation of large hospitals in the 340B program.
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/340b-past-and-present

National Drug Take Back Day

PhRMA  |  Blog Post

Like we stated before, law enforcement oversight is needed and programs should be structured to prevent theft or diversion of unused medication and protect patient privacy.
http://catalyst.phrma.org/national-drug-take-back-day

Statement Regarding GAO Report on Drug Prices

PhRMA  |  Press Release

PhRMA companies are leading the way in the search for new cures.
https://www.phrma.org/press-release/statement-regarding-gao-report-on-drug-prices

You have reviewed the first 125 results out of 2219. Each page contains 25 results. You're on page 5.

prev 1 2 3 4 5 6 next